SOPHiA GENETICS CSO reports initial share holdings
SOPHiA GENETICS SA filed an initial ownership report for Chief Scientific Officer Xu Zhenyu, detailing his existing equity position.
Rhea-AI Filing Summary
SOPHiA GENETICS SA filed an initial ownership report for Chief Scientific Officer Xu Zhenyu, detailing his existing equity position. He directly holds 537,724 ordinary shares, including 115,002 shares issuable under restricted stock units that vest over time, and 147,840 shares that have been pledged under lending arrangements. He also holds multiple share options over ordinary shares with expirations ranging from 2027 to 2035; some options are already fully vested, while others vest in monthly or quarterly installments through dates specified in the footnotes. The filing lists these holdings and does not show any new purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
Xu Zhenyu
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Share Option (Right to Buy) — 820,370 contracts (Direct);
Ordinary Shares — 537,724 shares (Direct)
Footnotes (6)
- F1. 147,840 ordinary shares have been pledged pursuant to lending arrangements.
- F2. Includes 115,002 ordinary shares issuable upon settlement of four restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 2,704 ordinary shares from a May 18, 2022 grant vesting in equal monthly installments through May 18, 2026; (ii) 37,833 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iii) 32,027 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (iv) 42,438 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.
- F3. The share options are fully vested and exercisable.
- F4. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.
- F5. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.
- F6. The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does SOPH's Form 3 show about Chief Scientific Officer Xu Zhenyu's holdings?
The Form 3 shows that Chief Scientific Officer Xu Zhenyu directly holds 537,724 ordinary shares of SOPHiA GENETICS SA. This total includes shares subject to restricted stock units and reflects his existing equity position, rather than new purchases or sales.
How many SOPH restricted stock units does Xu Zhenyu hold according to the Form 3?
Xu Zhenyu holds 115,002 ordinary shares issuable upon settlement of four restricted stock unit grants. These RSUs vest monthly or quarterly between May 2026 and April 2028, with one grant vesting 50% on April 2, 2026 before continuing in installments.
What stock options in SOPHiA GENETICS does Xu Zhenyu report on the Form 3?
Xu Zhenyu reports several share options giving rights to buy SOPHiA GENETICS ordinary shares. These options cover multiple grants with expirations from 2027 through 2035, with some fully vested and others vesting in monthly or quarterly installments as described in the footnotes.
Does SOPH's Form 3 indicate any recent buying or selling by Xu Zhenyu?
No. The Form 3 functions as an initial statement of beneficial ownership and lists existing share and option positions. The summarized data shows holding entries only, with no reported open‑market purchases, sales, or option exercises by Xu Zhenyu.
How do the RSU grants for Xu Zhenyu at SOPHiA GENETICS vest over time?
Four RSU grants vest over several years: one vests monthly through May 18, 2026, two vest quarterly through April 3, 2027 and April 2, 2028, and one vests 50% on April 2, 2026 with the remainder in quarterly installments through April 2, 2027.
AI-generated analysis. How Rhea-AI works. Not financial advice.
